Bringing cures for gastrointestinal disorders within reach

By leveraging an innovative discovery platform, Curileum Discovery is developing an approach based on stem cell drugs that has the potential to cure a wide range of gastrointestinal disorders.

Go to the profile of Curileum Discovery Ltd
Mar 02, 2017
0
0

Download the full PDF

Gastrointestinal problems are among the most commonly reported symptoms in the developed world, affecting up to one-third of individuals in Western countries. Up to three-quarters of outpatient diabetics and one-quarter of elderly individuals report gastrointestinal complaints that may be severe enough to substantially compromise their quality of life. With a market approaching $35 billion, treatment of the symptoms of serious chronic gastrointestinal disorders is currently the fastest-growing area in medicine.

Curileum Discovery is an emerging London-based regenerative medicine company focused on revealing the underlying causes of serious gastrointestinal diseases. By using an innovative discovery platform, Curileum is identifying new stem cell therapeutic targets in intestinal mucosal, immune and nerve tissues. Rather than simply treating symptoms, Curileum’s stem-cell-drug-based approach holds promise for curing patients with inflammatory bowel disease, colorectal cancer, irritable bowel disease and conditions associated with chronic gastrointestinal complaints.

Regenerative medicine promises to revolutionize patient care by repairing or replacing damaged cells and restoring integrity and function to tissues. Effective tissue regeneration requires the activation of endogenous stem cells, rare cells in tissues that are the very source of lifelong tissue renewal. “Harnessing three decades of stem cell drug discovery and development experience, we are unlocking a whole new area of therapeutic targets to kill defective stem cells, control inflammation that surrounds damaged tissues and activate healthy stem cells to restore health to the intestine,” said Curileum’s founder and CEO Jeff Moore.

Advanced stem cell assays

The gastrointestinal tract is highly vulnerable to damage, with only a single layer of epithelial cells separating the body from adverse factors in the gut environment. Degradation of this mucosal lining leads to tissue inflammation and disease (Fig. 1). Exposure of intestinal stem cells to toxic insults might never lead to overt clinical symptoms, but chronic stress and accumulating stem cell defects can further compromise the integrity and function of the intestinal barrier. A weakened intestinal barrier precedes the onset of type 1 diabetes and inflammatory bowel disease, indicating a genetic predisposition for disease.


Figure 1: Degradation of the single-cell lining of the intestine. Bacterial toxins are allowed to permeate mucosal tissue and activate a potent inflammatory response. Chronic inflammation can lead to cancer, seriously disrupt intestinal function, and cause nerve pain.

Using advanced in vitro assays with intestinal mucosal, immune and nerve tissue cells, Curileum is shedding new light on the biological properties and molecular gene signatures associated with the progression of healthy to diseased intestinal stem cells in the context of chronic inflammation and aging. Endoscopic biopsies of diseased tissue, adjacent inflamed tissue and nearby healthy intestinal tissue in an individual provide a unique opportunity to elucidate by pairwise analyses the steps leading to inflammatory bowel disease and cancer.

Direct comparison of multiple samples collected from an individual over time is particularly informative for understanding disease progression and responses to experimental and standard-of-care drugs. Examination of in vitro cultures of intestinal tissue stem cells at the molecular level in time-course experiments can identify the transcriptional signals that trigger stem cell self-renewal, proliferation, differentiation and apoptosis.

Curileum scientists can also use whole-genome sequencing to further analyze genetic variations and defects in intestinal stem cells. These stem cell defects are masked in the presence of the native supporting microenvironment in vivo. But the intrinsic growth properties of intestinal stem cells are revealed when the cells are cultured in vitro. The company’s discovery platform for human disease was previously validated in animal models with the delivery of new stem cell targets in a regenerative medicine collaboration with the Novartis Institutes for BioMedical Research.

Curileum is leveraging this resource and its discovery platform to develop biomarkers to inform patient care and support clinical development. Assessments of intestinal stem cell health have the potential to identify gastrointestinal disease predisposition and early-stage disease, thereby providing opportunities for early intervention.

First drug discovery program in Crohn’s disease

Curileum’s operations are based in northwest London, adjacent to St Mark’s Hospital—one of the only hospitals in the world that specializes entirely in intestinal and colorectal medicine, and a national and international referral center for intestinal and colorectal disorders. With access to a large supply of patient tissues and an open-innovation model to facilitate collaborations with leading academic clinicians, the company’s scientists can rapidly test hypotheses on stratified patient populations to discover and support target development.

Because of the limited availability of healthy human intestinal tissues, Curileum scientists have turned to the porcine model as a surrogate healthy benchmark for ineffective or defective patient stem cells. Baseline culture conditions are sufficient for the growth of porcine intestinal mucosal organoids. The company believes it has established stem cell organoid cultures from anal skin for the first time—humans require general anesthesia. The anorectal in vitro models are supporting the company’s program to discover and develop topical drugs that act directly on stem cells to more effectively manage inflammation and activate stem cells to heal anal fistulas, particularly where abscesses form under the skin of the anal canal and tunnel to create skin ruptures—an occurrence in up to one-third of people with Crohn’s disease.

Curileum is leveraging a front-end drug discovery module that plugs into pharmaceutical companies’ development pipelines to engage those companies in discussions about partnering on the Crohn’s anal fistula program and additional programs in gut hyperpermeability and in oncology for familial adenomatous polyposis. Curileum has a proven track record of delivery, along with streamlined business, legal and projectmanagement capabilities in its discovery and development partnerships with pharmaceutical companies. “Through these collaborations, we expect to unlock a whole new area of stem-cell-focused diagnostic and therapeutic targets in the gastrointestinal tract having broad applications in metabolic disease, aging, chronic inflammation and cancer,” Moore said.

Contact details

Jeff Moore, CEO

Curileum Discovery Ltd.

London, UK

Tel: +44 (0)7975 866170

E-mail: jeff.moore@curileum.com


ADVERTISER RETAINS SOLE RESPONSIBILITY FOR CONTENT

Go to the profile of Curileum Discovery Ltd

Curileum Discovery Ltd

Curileum Discovery Ltd is a newly funded regenerative medicine company in London identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues. We are engaging pharmaceutical collaborative partnerships in IBD, cancer, and conditions with major GI complications (diabetes and ageing) to discover a whole new range of novel, validated therapeutic targets for our partners’ development pipelines. Our hypothesis-driven approach focuses on targeting intestinal stem cells with small molecule or biologic therapeutics to correct imbalances in the number or functional properties of cells that contribute to disease pathologies: killing defective or ineffective stem cells, managing inflammation, and activating healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal, to restore health to the intestine. Our operations are based on the campus of St Mark's Hospital in North West London, a major tertiary care centre solely dedicated to intestinal and colorectal medicine (20k endoscopies/year). With access to a large supply of patient tissues and leading clinical collaborators, we can rapidly test hypotheses on defined patient populations to discover and support target development for therapeutics and molecular diagnostics to improve health of patients.

No comments yet.